XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Schedule of Revenue Recognized in Statements of Profit or Loss (Detail) - EUR (€)
€ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disclosure of operating segments [line items]        
Revenue from the rendering of services (recognized over time) € 226 € 779 € 395 € 2,091
Sale of clinical supply (recognized at a point in time) 217   217 246
"Right-to-use" licenses (recognized at a point in time) 579 657 1,155 1,324
Total revenue 1,022 1,436 1,767 3,661
Revenue by geographical location        
Total revenue 1,022 1,436 1,767 3,661
VISEN Pharmaceuticals [Member]        
Disclosure of operating segments [line items]        
Total revenue 913 1,436 1,550 3,661
Revenue by geographical location        
Total revenue 913 1,436 1,550 3,661
Other collaboration partners [Member]        
Disclosure of operating segments [line items]        
Total revenue 109   217  
Revenue by geographical location        
Total revenue 109   217  
North America [member]        
Disclosure of operating segments [line items]        
Total revenue 688 657 1,373 1,324
Revenue by geographical location        
Total revenue 688 657 1,373 1,324
China [member]        
Disclosure of operating segments [line items]        
Total revenue 334 779 394 2,337
Revenue by geographical location        
Total revenue € 334 € 779 € 394 € 2,337